INTERFERENCE DIGEST

Interference No. 105,619	Paper No.		
Name: David J. Pinsky et al.			
Serial No.: 10/679,135	Patent No.		
Title: Methods for treating ischemic disorders using	ng carbon monoxide		
Filed: 10/03/03			
Interference with Bach et al.	·		
DECISION ON	MOTIONS		
Administrative Patent Judge,	Dated,		
<u> </u>			
FINAL DEC	CISION		
	Board of Patent Appeals and Interferences,		
Court,			
REMAR	RKS		
·			

This should be placed in each application or patent involved in interference in addition to the interference letters.



UNITED STATES PATENT AND TRADEMARK OFFICE

DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE BOARD OF PATENT APPEALS AND INTERFERENCES BOX INTERFERENCE, WASHINGTON, D.C. 20231

> Filed by: Judge Fred E. McKelvey Telephone: 571-272-4683 Facsimile: 571-273-0042

Applicants: PINSKY

Application No.: 10/679,135

Filed: 10/03/03

For: Methods for treating ischemic disorders using

carbon monoxide

The above-identified application or patent has been forwarded to the Board of Patent Appeals and Interferences because it is adjudged to interfere with another application or patent. An interference has been declared. The interference is designated as No. 105,619.

Notice is hereby given the parties of the requirement of the law for filing in the Patent and Trademark Office a copy of any agreement "in connection with or in contemplation of the termination of the interference." 35 U.S.C. § 135(c).

/Fred E. McKelvey/ FRED E. McKELVEY Senior Administrative Patent Judge

BoxInterferences@uspto.gov Paper 1	
Telephone: 571-272-4683 Entered: 25 March 200	8
UNITED STATES PATENT AND TRADEMARK OFFICE	
BOARD OF PATENT APPEALS AND INTERFERENCES	
Technology Center 1600	
	
· · · · · · · · · · · · · · · · · · ·	
MIGUEL P. SOARES and JEANNE GOSE,	
D. 4 . 4 7 220 400 D2	
Junior Party,	
· V.	
DAVID I PINSKV DAVID M STERNI	
·	
and CHARLES J. I RESTROMEOWE,	
Application 10/679 135	
Somoi i arty,	
·	
DECLARATION	
	UNITED STATES PATENT AND TRADEMARK OFFICE BOARD OF PATENT APPEALS AND INTERFERENCES Patent Interference 105,619 McK Technology Center 1600 FRITZ H. BACH, LEO E. OTTERBEIN, MIGUEL P. SOARES and JEANNE GOSE, Patent 7,238,469 B2, Junior Party, v. DAVID J. PINSKY, DAVID M. STERN and CHARLES J. PRESTIGIACOME, Application 10/679,135, Senior Party,

1 2 3	Part A Declaration of Interference
4	An interference is declared between the above-identified parties.
5	35 U.S.C. § 135(a); 37 CFR § 41.203(b).
6	Details of the application, patent, counts and claims designated as
7	corresponding or as not corresponding to the counts appear in Parts E and F
8	of this DECLARATION.
9 10 11 12	Part B Judge Managing the Interference
13	Senior Administrative Patent Judge Fred E. McKelvey has been
14	designated to manage the interference. 37 CFR § 41.104(a).
15 16 17 18	Part C Standing Order
19	A Trial Division STANDING ORDER (3 Jan. 2006) (Paper 2)
20	accompanies this DECLARATION.
21	The STANDING ORDER applies to this interference, including the
22	provisions related to Electronic Filing. See ¶ 105, pages 17-20.
23 24 25	Part D Initial Conference Call and Motions Lists
26	Conference Call
27	A conference call to discuss the interference is set for:
28	3:00 p.m. (1500 hours EDT) on 14 May 2008.
29	The Board will initiate the conference call.
30	

1	Motions Lists
2	On or before:
3	Noon (1200 hours EDT) on 09 May 2008,
4	each party shall file, and on or before:
5	5:00 p.m. (1700 hours EDT) on 09 May 2008,
6	each party shall serve a notice stating the relief the party requests, i.e., a
7	motions list including motions the party seeks authorization to file. 37 CFR
8	§ 41.120(a); STANDING ORDER ¶ 204 (Paper 2, page 58).
9	The default procedure for filing and serving motions lists is that
10	motions lists are to be filed before being served.
11	By filing before service, one party will not have access to an
12	opponent's motions list prior to the filing of the party's motions list.
13	Nevertheless, the parties may mutually agree to discuss and serve
14	motions lists at any time prior to the date and time motions lists are due.
15	The following shall be included in motions lists.
16	(1) Proposed motion for benefit (i.e., to be accorded an
17	earlier constructive reduction to practice) must identify the application(s) for
18	which benefit will be sought.
19	(2) Proposed motion to attack benefit must identify the
20	application(s) to be attacked.
21	(3) Proposed motion seeking judgment against an opponent
22	based on alleged unpatentability must identify the statutory basis for the
23	alleged unpatentability and:
24	(a) if based on prior art, identify the prior art;
25	(b) if based on the first paragraph of 35 U.S.C. § 112,
26	(i) identify whether written description, enablement or best mode will be the

1	basis for the motion, and (ii) briefly identify the basis for any alleged		
2	unpatentability;		
3	(c) if based on an alleged failure to comply with		
4	35 U.S.C. § 135(b), briefly identify the reason;		
5	(d) if based on the second paragraph of 35 U.S.C.		
6	§ 112, identify the limitation which is believed to be indefinite.		
7	(4) Proposed motion based on no interference-in-fact shall		
8	briefly identify the reason no interference-in-fact is believed to exist.		
9	(5) Proposed motion to designate additional claims as		
10	corresponding to a count or as not corresponding to a count shall identify the		
11	claims involved.		
12	(6) Proposed motion to add or substitute a new count shall		
13	explain why the added or substitute count is necessary.		
14	A motions list shall not contain any "reservation clause" whereby a		
15	party purports to reserve a right to file additional motions. Additional		
16	motions are those authorized by the Board consistent with the rules.		
17	A sample schedule for taking action during the motions phase of the		
18	interference appears as Form 2 (page 69) of the STANDING ORDER.		
19	Counsel are encouraged to discuss the schedule prior to the		
20	conference and agree to on times for taking action generally consistent with		
21	the sample schedule.		
22	A typical motions phase last about eight (8) months.		
23	The parties should be prepared at the conference to justify any request		
24	for shorter or longer time periods.		

1		Part E
2 3	Υ.	dentification of the Parties
3 4	Identification of the Parties Assignment of Exhibit Numbers	
5		iating Settlement Discussions
6		
7 8		Junior Party
9	Inventors:	Fritz H. Bach, MA
10		Leo E. Otterbein, PA
11		Miguel P. Soares, MA
12		Jeanne Gose, MA
13		77 G D G 220 4(0 D2
14	Patent:	U.S. Patent 7,238,469 B2
15		issued 03 July 2007
16		based on application 10/177,930, filed 21 June 2002
17		med 21 June 2002
18 19	Title:	Carbon monoxide improves outcomes in tissue
20	Title.	and organ transplants and suppresses apoptosis
21		and organization in the second
22	Real party in interest:	Beth Israel Deaconess Medical Center, Inc., and
23		Yale University
24		
25		Senior Party
26		m 'II' I MT
27	Inventors:	David J. Pinsky, MI
28		David M. Stern, GA Charles J. Prestigiacome, NJ
29		Charles J. Flestiglacome, 143
30	A mulication:	Application 10/679,135,
31 32	Application:	filed 03 October 2003
33		
34	Title:	Methods for treating ischemic disorders using
35		carbon monoxide
36		
37	Real party in interest:	The Trustees of Columbia University in the
38	- .	City of New York
39		

1	<u> </u>	Assignment of Exhibit Numbers
2	Senior party:	Exhibit Numbers 1001 through 1999.
3	Junior party:	Exhibit Numbers 2001-2999.
4	Board:	Exhibit Numbers 3001-3999.
5 6 7 8	I <u>STANDIN</u>	nitiating Settlement Discussions G ORDER ¶ 126.1 (Paper 2, pages 40-41)
9	The senior party	is responsible for initiating settlement discussions
10	required by the STAN	
11 12	C	Part F Counts and Claims of the Parties
13 14		Count 1 ¹
15	A method of tra	nsplanting a liver, the method comprising:
16	` ,	ninistering to a donor by inhalation a gaseous
17	pharmaceutical compo	osition comprising about 0.0000001% to about 0.3% ²
18	carbon monoxide;	

¹ The footnotes are not part of the count.

² The "about 0.0000001% to about 0.3%" comes from U.S. Patent 7,238,469 B2, col. 11:55.

- (b) obtaining from the donor a liver;³ and
- 2 (c) transplanting the liver into a recipient, wherein (1) the
- 3 amount of carbon monoxide administered to the donor in step (a) is
- 4 sufficient to enhance survival or function of the liver after transplantation
- 5 into the recipient or (2) the amount and period of time carbon monoxide is
- 6 administered is sufficient to protectively treat the subject.⁴

1

The organs set out in Counts 1-3 are limited to those explicitly claimed by both parties. See claim 1 of Bach U.S. Patent 7,238,469 B2 and claim 65 of Pinsky application 10/679,135. In addition, it is not apparent from the prior art how the use of the method for a liver would render unpatentable under 35 U.S.C. § 103 use of the method for a heart or pancreas or vice versa. Accordingly, there are three counts. Cf. Godtfredsen v. Banner, 598 F.2d 589, 592, 202 USPQ 7, 10 (CCPA 1979): "Where, as here, the parties both disclose the same three species, that fact does not justify including those species in a single count as members of a Markush group if the Examiner has determined that the three species are patentably distinct inventions. If such a count were permitted, then the party who proved the earliest date of invention as to any one of the members of the group would be awarded priority as to the entire count, i.e., as to all three members. It is not considered that such a result would be consonant with the primary purpose of an interference or within the intent of 35 U.S.C. § 135, since there would be no determination of priority as to each of the common [patentably distinct] inventions claimed by the parties [emphasis in original]."

Claim 1 of Bach U.S. Patent 7,238,469 B2 uses the language "sufficient to enhance survival or function". Claim 46 of Pinsky application uses the language "sufficient to protectively treat the subject". The (1) and (2) limitations in step (c) of the count are alternative limitations, one based on the language of the Bach patent and the other based on the language of the Pinsky application. Priority proofs must fall within the scope of the count. See 37 C.F.R. § 41.201 (definition of "count"), codifying holdings in cases such as Squires v. Corbett, 560 F.2d 424, 433 (CCPA 1977) (count is merely a vehicle for contesting priority and determines what evidence is relevant on the issue of priority). In view of "indefiniteness" concerns discussed in Halliburton Energy Services, Inc. v. M-I LLC, 514 F.3d 1244, 85 USPQ2d 1654 (Fed. Cir. 2008), the parties are advised that the "sufficient to enhance"

1	The claims of the p	parties are:
2	_	
3	Bach:	1-54
4		46 40 51 52 56 62 65 and 90
5	Pinsky:	46, 49-51, 53, 56-62, 65 and 89
6		1. 0
7	The claims that co	rrespond to Count 1 are:
8		140.54
9	Bach:	1-14, 20-36 and 49-54
10		10.10.11.50.56.60.65
11	Pinsky:	46, 49-51, 53, 56-62, 65 and 89
12		
13	The claims that do	not correspond to Count 1 are:
14		
15	Bach:	15-19 and 37-48
16		
17	Pinsky:	None
18		
19	As to Count 1, the	parties are accorded an earlier constructive
20	reduction to practice (i.e	, benefit for the purpose of priority) of the
21	following applications:	
22	Bach:	None
23		
24	Pinsky:	Application 09/671,100
25		filed 27 September 2000
26		
27		International application PCT/US99/07175,
28		filed 01 April 1999
-		

and "sufficient to protectively" language gives the Board pause. The parties will be expected to educate the Board on why the language is sufficiently clear to permit proofs on priority and in particular the meanings of "enhance" and "protectively".

1	Count 2	
2	A method of transplanting a heart, the method comprising:	
3	(a) administering to a donor by inhalation a gaseous	
4	pharmaceutical composition comprising about 0.0000001% to about 0.3%	
5	carbon monoxide;	
	1 1 1 1 1 1	
6		
7	(c) transplanting the heart into a recipient, wherein (1) the	
8	amount of carbon monoxide administered to the donor in step (a) is	
9	sufficient to enhance survival or function of the heart after transplantation	
10	into the recipient or (2) the amount and period of time carbon monoxide is	
11	administered is sufficient to protectively treat the subject.	
12		
13	The claims of the parties are:	
14		
15	Bach: 1-54	
16	Pinsky: 46, 49-51, 53, 56-62, 65 and 89	
17 18	Finsky. 40, 49-31, 33, 30 02, 00 3111	
19	The claims that correspond to Count 2 are:	
20	10.00.00.40.40.40.54	
21	Bach: 1-13, 16, 20-33, 40-42 and 49-54	
22	Pinsky: 46, 49-51, 53, 56-62, 65 and 89	
23 24	r msky. 40, 45 51, 55, 55 54,	
25	The claims that do not correspond to Count 2 are:	
26	14.15.17.10.24.30 and 43-48	
27	Bach: 14-15, 17-19, 34-39 and 43-48	
28 29	Pinsky: None	
30		

1	As to Count 2, the parties are accorded an earlier constructive		
2	reduction to practice (i.e., benefit for the purpose of priority) of the		
3	following applications:		
4	Bach: No	one	
5 6 7 8		pplication 09/671,100 led 27 September 2000	
9		Count 3	
10	A method of transplanting a pancreas, the method comprising:		
11	(a) adminis	tering to a donor by inhalation a gaseous	
12	pharmaceutical composition	n comprising about 0.0000001% to about 0.3%	
13	carbon monoxide;		
14	(b) obtainin	g from the donor a pancreas; and	
15	(c) transpla	nting the pancreas into a recipient, wherein	
16	(1) the amount of carbon monoxide administered to the donor in step (a) is		
17	the managed after		
18	transplantation into the recipient or (2) the amount and period of time carbon		
19	monoxide is administered i	s sufficient to protectively treat the subject.	
20 21 22	The claims of the pa	rties are:	
23	Bach: 1	-54	
24 25	Pinsky: 4	6, 49-51, 53, 56-62, 65 and 89	
26	,		
27 28		espond to Count 3 are:	
29		-13, 17, 20-33, 43-45 and 49-54	
30 31 32	Pinsky: ²	46, 49-51, 53, 56-62, 65 and 89	

1	The claims that do	not correspond to Count 3 are:
2		1.46.40
3	Bach:	14-16, 18-19, 34-42 and 46-48
4		
5	Pinsky:	None
6		1 1 Singaportunativa
7	As to Count 3, the	parties are accorded an earlier constructive
8	reduction to practice (i.e	., benefit for the purpose of priority) of the
9	following applications:	
10	Bach:	None
11		
12	Pinsky:	Application 09/671,100
13		filed 27 September 2000
14		

1 2	Part G Heading to be Used on Papers
3 4	The following heading shall be used on all papers filed in this
5	interference [STANDING ORDER ¶ 106.11 (Paper 2, page 20)].
6 7 8 9	Filed by: [name of party] [Name of attorney] [Email address of attorney] [Telephone number of attorney] Paper _ Date filed: [enter date emailed to Board]
11 12 13	UNITED STATES PATENT AND TRADEMARK OFFICE BOARD OF PATENT APPEALS AND INTERFERENCES
14 15 16 17	Patent Interference 105,619 McK Technology Center 1600
18 19 20	FRITZ H. BACH, LEO E. OTTERBEIN, MIGUEL P. SOARES and JEANNE GOSE,
21 22 23	Patent 7,238,469 B2, Junior Party,
242526	· v.
27 28 29	DAVID J. PINSKY , DAVID M. STERN and CHARLES J. PRESTIGIACOME,
30 31 32	Application 10/679,135, Senior Party,
33 34	Title of Paper, e.g., BACH SUBSTANTIVE MOTION 1

1 2	Part H Order Form for Requesting File Copies
3	When requesting file copies, a party shall use STANDING ORDER
4	Form 4 (page 71).
5	Use of form 4 will expedite processing of any request.
6	a party should attach to any request for file copies a photocopy of
7	Part E of this DECLARATION with a hand-drawn circle around the patent
8	and application files for which a copy of a file wrapper is requested.
9	The parties are advised that a single order for file copies may be filled
0	by the Office of Public Records at more than one time. STANDING
1	ORDER ¶ 109.2 (Paper 2, pages 25-27).
12 13 14	Part I Required Paragraph of Affidavits and Declarations
16	The Board has experienced cases in which a witness has belatedly
17	advanced reasons why the witness would be unable to appear for cross
18	examination at a reasonable time and place in the United States.
19	Consequently, to prevent surprise and hardship to the party relying on
20	the testimony of a witness, the following paragraph must be included on the
21	signature page of all affidavits (including declarations) filed in this case.
22	STANDING ORDER ¶ 157.2 (Paper 2, pages 52-53).
23 24	In signing affidavit (declaration), I understand that the affidavit
25	(declaration) will be filed as evidence in a contested case before
26	the Board of Patent Appeals and Interferences of the United
27	States Patent and Trademark Office. I also acknowledge that I
28	may be subject to cross examination in the case and that cross

1	e	examination will take place within the United States. If cross
2	e	examination is required of me, I will appear for cross
3	ϵ	examination within the United States during the time allotted
4	f	for cross examination.
5		
6		
7		
8		
9		/ss/ Fred E. McKelvey)
10		FRED E. McKELVEY)
11		Senior Administrative Patent Judge)
12		
13		
14	Entered at:	
15		
16	Kailua, HI	•
17	25 March 200	08

```
cc (via Federal Express):
 1
 2
    Attorney for Bach
 3
    (real party in interest
 4
    Beth Israel Deaconess Medical Center, Inc., and Yale University):
 5
 6
     Janis K. Fraser, Esq.
 7
    FISH & RICHARDSON P.C.
 8
    225 Franklin Street
 9
     Boston, MA 02110
10
11
                617-542-5070
12
     Tel:
                None
13
     Fax:
                None
14
     Email:
15
16
     Attorney for Pinsky
17
     (real party in interest
18
     The Trustees of Columbia University in the City of New York):
19
20
     John P. White, Esq.
21
     COOPER & DUNHAM LLP
22
     1185 Avenue of the Americas
23
     New York, NY 10036
24
25
                 212-278-0400 (main)
     Tel:
26
                 212-278-0421 (White)
27
     Tel:
                 None
28
     Fax:
29
     Email:
                 None
30
```

31